Valuation: Kelyniam Global, Inc.

Market Cap 7.8M 6.93M 6.47M 5.9M 11.13M 750M 11.23M 78.32M 30.35M 384M 29.3M 28.67M 1.23B P/E 2022
-24.8x
P/E 2023 -8.35x
Enterprise Value 8.43M 7.49M 6.99M 6.37M 12.01M 810M 12.13M 84.58M 32.77M 414M 31.64M 30.95M 1.33B EV / Sales 2022
0.99x
EV / Sales 2023 0.92x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Executive Officer - 2018-01-08
Director of Finance/CFO - 2020-01-31
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 2018-01-08
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+14.19%+11.45% - - 6.56M
+0.35%-2.99%+24.73%+32.07% 242B
+1.09%-4.65%+1.77%+0.15% 150B
-2.32%-3.27%-11.53%+32.87% 138B
-1.46%-3.01%-55.73%-19.33% 61.74B
-0.05%-1.32%+11.09%+23.08% 49.08B
+0.66%+0.19%-19.29%-21.24% 47.43B
+0.66%-2.90%+20.97%+51.29% 47.3B
-3.05%-2.62%-9.13%+35.86% 44.25B
-0.08%-1.92%+32.09%+57.18% 41.78B
Average +1.26%-2.50%-0.56%+21.33% 91.4B
Weighted average by Cap. +0.15%-3.27%+3.37%+21.48%

Financials

2022 2023
Net sales 3.02M 2.68M 2.5M 2.28M 4.3M 290M 4.34M 30.28M 11.73M 148M 11.33M 11.08M 476M 2.67M 2.37M 2.22M 2.02M 3.81M 257M 3.84M 26.82M 10.39M 131M 10.03M 9.82M 421M
Net income -97.56K -86.68K -80.9K -73.74K -139K -9.38M -140K -979K -379K -4.79M -366K -358K -15.39M -218K -194K -181K -165K -311K -21M -314K -2.19M -850K -10.74M -820K -802K -34.46M
Net Debt 560K 497K 464K 423K 798K 53.82M 806K 5.62M 2.18M 27.51M 2.1M 2.06M 88.3M 623K 553K 517K 471K 888K 59.88M 896K 6.25M 2.42M 30.61M 2.34M 2.29M 98.25M
Logo Kelyniam Global, Inc.
Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company specializing in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient’s computed tomography (CT) data, its 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours. It distributes its products throughout the United States via independent distributors and sales representatives.
Employees
-